<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728427</url>
  </required_header>
  <id_info>
    <org_study_id>SPCCVC-TUC</org_study_id>
    <nct_id>NCT02728427</nct_id>
  </id_info>
  <brief_title>Multicenter Study on Suprapubic Catheterization Versus Transurethral Catheterization in Laparoscopic Surgery for Rectal Cancer</brief_title>
  <acronym>MSSPC</acronym>
  <official_title>Multicenter Study on Comparing Suprapubic Catheterization Versus Traditional Transurethral Catheterization in Laparoscopic Surgery for Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compared with traditional open proctectomy, laparoscopic surgery is associated with less
      pain, earlier recovery, and better cosmetic outcome, and its long-term oncologic outcomes
      have been demonstrated. However, the rate of urinary dysfunction after rectal cancer surgery
      was about 19-38% because of mesorectal excision. The type of drainage is unclear. Some
      studies show that the rates of urinary tract infection, second catheterization, and urinary
      symptom are lower with suprapubic catheterization (SPC) than with transurethral
      catheterization (TUC). Moreover，SPC allows for testing the bladder voiding without drainage
      removal. Furthermore，SPC using central venous catheter(CVC) is less invasive.

      Currently, there is lack of randomized controlled trial(RCT) to compare SPC with TUC.
      Therefore, investigators perform this prospective randomized trial to compare SPC using CVC
      with TUC in laparoscopic surgery for rectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Catherization time</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of catheterization</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter-Associated Urinary Tract Infection</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>5 days</time_frame>
    <description>Postoperative pain is recorded using the visual analog scale (VAS) pain score tool from the surgery day to the fifth day after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostatic Symptom Score</measure>
    <time_frame>30 days</time_frame>
    <description>The International Prostatic Symptom Score is recorded from the day before surgery to the 30th day after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first ambulation</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary extravasation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematuria</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter obstruction</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Suprapubic Catheterization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transurethral Catheterization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transurethral catheterization using Foley catheter will be performed for patients in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suprapubic catheterization using central venous catheter(CVC-2 7F)</intervention_name>
    <description>Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.</description>
    <arm_group_label>Suprapubic Catheterization</arm_group_label>
    <other_name>SPCCVC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transurethral catheterization using Foley catheter</intervention_name>
    <description>Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.</description>
    <arm_group_label>Transurethral Catheterization</arm_group_label>
    <other_name>TUC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Pathological rectal carcinoma

          -  Male patients

          -  Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale

          -  ASA (American Society of Anesthesiology) score class I, II, or III

          -  Laparoscopic surgery for rectal cancer

          -  Written informed consent

        Exclusion Criteria:

          -  Emergency surgery due to complication (obstruction or perforation) caused by rectal
             cancer

          -  Preoperative T4b according to the 7th Edition of AJCC Cancer Staging Manual

          -  Basic diseases of urinary system (urinary bladder stones and tumors, prostate cancer,
             neurogenic bladder, urethral stricture) that affect voiding function

          -  History of previous pelvic surgery

          -  Severe mental disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoxin Li, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group; Nanfang Hospital, Southern Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guoxin Li, M.D., Ph.D.</last_name>
    <phone>+86-138-0277-1450</phone>
    <email>gzliguoxin@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jun Yan, M.D., Ph.D.</last_name>
    <phone>+86-138-2506-6546</phone>
    <email>yanjunfudan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fujian Provincial Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350-001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fangqin Xue, M.D.</last_name>
      <phone>+86-137-9995-9360</phone>
      <email>xuefangqingsl@sina.com</email>
    </contact>
    <investigator>
      <last_name>fangqin xue, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350-014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Zang, M.D.</last_name>
      <phone>+86-13805066578</phone>
      <email>894434459@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Chunkang Yang, M.D.</last_name>
      <phone>+86-13509333116</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510-515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoxin Li, M.D., Ph.D.</last_name>
      <phone>+86-138-0277-1450</phone>
      <email>gzliguoxin@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Yan, M.D., Ph.D.</last_name>
      <phone>+86-138-2506-6546</phone>
      <email>yanjunfudan@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.fimmu.com/index_com.html</url>
    <description>Southern Medical University, China</description>
  </link>
  <link>
    <url>http://www.nfyy.com/</url>
    <description>Nanfang Hospital, China</description>
  </link>
  <link>
    <url>http://www.caca.org.cn/</url>
    <description>Chinese Anti-Cancer Association</description>
  </link>
  <reference>
    <citation>Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MH, de Lange-de Klerk ES, Lacy AM, Bemelman WA, Andersson J, Angenete E, Rosenberg J, Fuerst A, Haglind E; COLOR II Study Group. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015 Apr 2;372(14):1324-32. doi: 10.1056/NEJMoa1414882.</citation>
    <PMID>25830422</PMID>
  </reference>
  <reference>
    <citation>Jayne DG, Brown JM, Thorpe H, Walker J, Quirke P, Guillou PJ. Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. Br J Surg. 2005 Sep;92(9):1124-32.</citation>
    <PMID>15997446</PMID>
  </reference>
  <reference>
    <citation>Maurer CA, Z'Graggen K, Renzulli P, Schilling MK, Netzer P, Büchler MW. Total mesorectal excision preserves male genital function compared with conventional rectal cancer surgery. Br J Surg. 2001 Nov;88(11):1501-5.</citation>
    <PMID>11683749</PMID>
  </reference>
  <reference>
    <citation>Bouchet-Doumenq C, Lefevre JH, Bennis M, Chafai N, Tiret E, Parc Y. Management of postoperative bladder emptying after proctectomy in men for rectal cancer. A retrospective study of 190 consecutive patients. Int J Colorectal Dis. 2016 Mar;31(3):511-8. doi: 10.1007/s00384-015-2471-8. Epub 2015 Dec 22.</citation>
    <PMID>26694925</PMID>
  </reference>
  <reference>
    <citation>Sethia KK, Selkon JB, Berry AR, Turner CM, Kettlewell MG, Gough MH. Prospective randomized controlled trial of urethral versus suprapubic catheterization. Br J Surg. 1987 Jul;74(7):624-5.</citation>
    <PMID>3304522</PMID>
  </reference>
  <reference>
    <citation>Ratnaval CD, Renwick P, Farouk R, Monson JR, Lee PW. Suprapubic versus transurethral catheterisation of males undergoing pelvic colorectal surgery. Int J Colorectal Dis. 1996;11(4):177-9.</citation>
    <PMID>8876274</PMID>
  </reference>
  <reference>
    <citation>Perrin LC, Penfold C, McLeish A. A prospective randomized controlled trial comparing suprapubic with urethral catheterization in rectal surgery. Aust N Z J Surg. 1997 Aug;67(8):554-6.</citation>
    <PMID>9287924</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Suprapubic Catheterization</keyword>
  <keyword>Transurethral Catheterization</keyword>
  <keyword>Rectal Cancer</keyword>
  <keyword>Laparoscopic Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

